Securities Code: 002424 Securities Abbreviation: ST Bai Ling Announcement No.: 2026-031 Guizhou Bai Ling Pharmaceutical Group Co., Ltd. Announcement on Participating in the 2026 Guizhou Regulatory Area Listed Companies Investor Collective Reception Day and 2025 Annual Performance Briefing
The Company and all members of the Board of Directors guarantee that the content of the information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Guizhou Bai Ling Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") disclosed the "2025 Annual Report" and its summary on the CNINFO website (www.cninfo.com.cn) on April 28, 2026. To strengthen communication and interaction with investors and to facilitate investors' further understanding of the Company's 2025 operating performance and other issues of concern, the Company will participate in the "2026 Guizhou Regulatory Area Listed Companies Investor Collective Reception Day and 2025 Annual Performance Briefing" organized by the Guizhou Securities Regulatory Bureau and Shenzhen All-Round Network Co., Ltd. The company will also solicit questions. The specific arrangements are as follows:
1. Arrangements for the Performance Briefing
Meeting Time: May 11, 2026, 15:30-17:30 Meeting Format: Online Remote Attendees: Mr. Niu Min, Director and General Manager; Mr. Chen Pei, Secretary of the Board (acting); Mr. Li Hongxing, Financial Controller; Mr. Hu Jian, Independent Director. Participation Method: Investors can log in to the special zone page at http://rs.p5w.net to participate in the exchange.